TY - JOUR
T1 - HY-specific induced regulatory T cells display high specificity and efficacy in the prevention of acute graft-versus-host disease
AU - Li, Jun
AU - Heinrichs, Jessica
AU - Haarberg, Kelley
AU - Semple, Kenrick
AU - Veerapathran, Anandharaman
AU - Liu, Chen
AU - Anasetti, Claudio
AU - Yu, Xue Zhong
N1 - Publisher Copyright:
© 2015 by The American Association of Immunologists, Inc.
PY - 2015/7/15
Y1 - 2015/7/15
N2 - Naturally derived regulatory T cells (Tregs) may prevent graft-versus-host disease (GVHD) while preserving graft-versus-leukemia (GVL) activity. However, clinical application of naturally derived regulatory T cells has been severely hampered by their scarce availability and nonselectivity. To overcome these limitations, we took alternative approaches to generate Ag-specific induced Tregs (iTregs) and tested their efficacy and selectivity in the prevention ofGVHDin preclinical models of bonemarrow transplantation.We selectedHY as a target Ag because it is a naturally processed, ubiquitously expressed minor histocompatibility Ag (miHAg) with a proven role in GVHD and GVL effect. We generated HY-specific iTregs (HY-iTregs) from resting CD4 T cells derived from TCR transgenic mice, in which CD4 cells specifically recognize HY peptide.We found that HY-iTregs were highly effective in preventing GVHD in male (HY+) but not female (HY2) recipients using MHC II-mismatched, parent-F1, and miHAg-mismatched murine bone marrow transplantation models. Interestingly, the expression of target Ag (HY) on the hematopoietic or nonhematopoietic compartment alone was sufficient for iTregs to prevent GVHD. Furthermore, treatment with HY-iTregs still preserved the GVL effect even against preestablished leukemia.We found that HY-iTregs were more stable in male than in female recipients. Furthermore, HY-iTregs expanded extensively in male but not female recipients, which in turn significantly reduced donor effector T cell expansion, activation, and migration into GVHD target organs, resulting in effective prevention of GVHD. This study demonstrates that iTregs specific for HY miHAgs are highly effective in controlling GVHD in an Ag-dependent manner while sparing the GVL effect.
AB - Naturally derived regulatory T cells (Tregs) may prevent graft-versus-host disease (GVHD) while preserving graft-versus-leukemia (GVL) activity. However, clinical application of naturally derived regulatory T cells has been severely hampered by their scarce availability and nonselectivity. To overcome these limitations, we took alternative approaches to generate Ag-specific induced Tregs (iTregs) and tested their efficacy and selectivity in the prevention ofGVHDin preclinical models of bonemarrow transplantation.We selectedHY as a target Ag because it is a naturally processed, ubiquitously expressed minor histocompatibility Ag (miHAg) with a proven role in GVHD and GVL effect. We generated HY-specific iTregs (HY-iTregs) from resting CD4 T cells derived from TCR transgenic mice, in which CD4 cells specifically recognize HY peptide.We found that HY-iTregs were highly effective in preventing GVHD in male (HY+) but not female (HY2) recipients using MHC II-mismatched, parent-F1, and miHAg-mismatched murine bone marrow transplantation models. Interestingly, the expression of target Ag (HY) on the hematopoietic or nonhematopoietic compartment alone was sufficient for iTregs to prevent GVHD. Furthermore, treatment with HY-iTregs still preserved the GVL effect even against preestablished leukemia.We found that HY-iTregs were more stable in male than in female recipients. Furthermore, HY-iTregs expanded extensively in male but not female recipients, which in turn significantly reduced donor effector T cell expansion, activation, and migration into GVHD target organs, resulting in effective prevention of GVHD. This study demonstrates that iTregs specific for HY miHAgs are highly effective in controlling GVHD in an Ag-dependent manner while sparing the GVL effect.
UR - http://www.scopus.com/inward/record.url?scp=84936762835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936762835&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1401250
DO - 10.4049/jimmunol.1401250
M3 - Article
C2 - 26048147
AN - SCOPUS:84936762835
SN - 0022-1767
VL - 195
SP - 717
EP - 725
JO - Journal of Immunology
JF - Journal of Immunology
IS - 2
ER -